Skip to main content
Equibles
AIM logo

AIM · AIM ImmunoTech Inc. · Metrics

Track AIM — free

Use AIM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AIM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.15 +0.00 (+0.13%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Nov 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Nov 12, 2026
Market Cap
$5.93M
Shares
39.92M
Volume · Nov 12 377.23K Avg daily vol (3M) 4.39M

AIM metrics

66 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.15
Market cap
$5.93M

Price action

23 metrics
Price change (1W)
-7.8%
Price change (30D)
-12.7%
Price change (3M)
-42.3%
Price change (6M)
-45.0%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
229.1%
Annualized volatility (3M)
72.5%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.2
RSI (14D)
38.8
Price vs SMA 50
-19.5%
Price vs SMA 200
—
Avg volume (3M)
4.39M
Relative volume
0.2
Average dollar volume
$981,526

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
39.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
47.6×
reciprocal yield 2.1%
P / book
0.6
reciprocal yield 171.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-315.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
50.0×
reciprocal yield 2.0%
EV / revenue historical average (5Y)
57.2×
reciprocal yield 1.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-04

Profitability

9 metrics
Gross margin
—
Operating margin
-11,724.2%
Trailing 12 months
Net margin
-15,021.1%
Gross profit (TTM)
−$1.41M
Operating profit (TTM)
−$11.14M
Net income (TTM)
−$14.27M
Trailing 12 months
Diluted EPS (TTM)
$-6.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.84
Book value per share
$-3.19

Growth

11 metrics
Revenue growth YoY
+4.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$95,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,154.6%
Year over year · more shares
Revenue CAGR (3Y)
-14.5%
Revenue CAGR (5Y)
-11.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-184.3%
Return on assets
-112.1%
Debt / equity
0.5
Current ratio
2.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.1
Interest coverage
-9.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$6.34M
Latest balance sheet
Cash & equivalents
$9.90M
Total assets
$12.73M
Total debt
$3.62M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.37M
Capital expenditures (TTM)
—
R&D (TTM)
$2.74M
SG&A (TTM)
—
Stock compensation (TTM)
$60,000
R&D / revenue
2,885.3%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
0
Institutional ownership
2.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.7%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+685.0%
Holder tenure
3.7
Price vs estimated holder cost
-69.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 2.5 days to cover
Days to cover
2.5d
Short-squeeze score
39 / 100

Insider activity

2 metrics
Net insider buying (90D)
$39,251
Insider-sentiment score
82 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 946644 CUSIP 00901B303 13F (30d) 14 filings 12 filers Visit website Investor relations